Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Adam D. Cohen, MD

Adam D. Cohen, MD Physician

Director, Myeloma Immunotherapy Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Cohen is employed by Penn Medicine.

About Dr. Adam D. Cohen

Recognized by America's Top Doctors for 2017

Recognized by Best Doctors in America 2016

Recognized in Philadelphia magazine's May 2018 Top Docs issue

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2007
  • Medical Oncology, 2005

Clinical Expertise:

  • Autologous Stem Cell Transplantation
  • Lymphoma
  • Multiple Myeloma
  • Waldenstrom Macroglobulinemia (WM)

Description of Clinical Expertise

Multiple Myeloma
POEMS syndrome
Monoclonal gammopathies
Waldenstrom's Macroglobulinemia

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Memorial Sloan-Kettering Cancer Center


American Association for Cancer Research, National American Society of Clinical Oncology, National American Society of Hematology, National Eastern Cooperative Oncology Group, National Independent Data and Safety Monitoring Committee, "Griffin" randomized trial of Daratumumab-RVD vs RVD for newly-diagnosed myeloma (NCT02874742), International Independent Response Adjudication Committee, RVD registration for newly-diagnosed myeloma (4 trials reviewed: IFM 2009, IFM 2013-04, PETHEMA GEM2005, PETHEMA GEM2012), International International Myeloma Society, International International Myeloma Working Group (IMWG), International

Hospital Affiliation

Dr. Cohen is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Cancer immunotherapy
Cellular therapy
Phase I trials
CAR T cells

Selected Publications:

Gumber Ramnika, Cohen Jordana B, Palmer Matthew B, Kobrin Sidney M, Vogl Dan T, Wasserstein Alan G, Nasta Sunita D, Bleicher Melissa B, Bloom Roy D, Dember Laura, Cohen Adam, Weiss Brendan M, Hogan Jonathan J: A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney international 94 (1): 199-205,2018.

Cohen Adam D: CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (38): e6-e15,2018.

Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight 3 (8): 2018.

Waxman Adam J, Clasen Suparna, Hwang Wei-Ting, Garfall Alfred, Vogl Dan T, Carver Joseph, O'Quinn Rupal, Cohen Adam D, Stadtmauer Edward A, Ky Bonnie, Weiss Brendan M: Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA oncology 4 (3): e174519,2018.

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson Jr. LD, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD: Targeting B-Cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma: A Dose-Escalation and Expansion Phase 1 Trial (BMA117159) Lancet Oncology : in press,2018.

Campbell KS, Cohen AD, Pazina T: Dissecting the Mechanism of NK Cell Activation by the SLAMF7 Antibody, Elotuzumab Frontiers in Immunology : in press,2018.

Shah Jatin J, Kaufman Jonathan L, Zonder Jeffrey A, Cohen Adam D, Bensinger William I, Hilder Brandi W, Rush Selena A, Walker Duncan H, Tunquist Brian J, Litwiler Kevin S, Ptaszynski Mieke, Orlowski Robert Z, Lonial Sagar: A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer 123 (23): 4617-4630,2017.

David C Fajgenbaum, Dustin Shilling, Helen L Partridge, Sheila K Pierson, Jason R Ruth, Christopher Sheild Nabel, Katie Stone, Vandana Chaturvedi, Michael B. Jordan, Adam D. Cohen, Vera Krymskaya, Arthur H Rubenstein, Frits van Rhee, and Thomas S Uldrick: Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach Blood (ASH Annual Meeting) 130 : #3593,2017.

Pazina Tatiana, James Ashley M, MacFarlane Alexander W, Bezman Natalie A, Henning Karla A, Bee Christine, Graziano Robert F, Robbins Michael D, Cohen Adam D*, Campbell Kerry S*: The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology 6 (9): e1339853,2017.

Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer, Simon F Lacey, Eric Lancaster, Dan T. Vogl, Brendan M Weiss, David E Ambrose, Anne Marie Nelson, Fang Chen, Gabriela Plesa, Irina Kulikovskaya, Vanessa Gonzalez, Minnal Gupta, Regina M Young, Karen Dengel, Laura O'keefe, Samantha Le, Celeste Richardson, Randi E. Isaacs, J. Joseph Melenhorst, Bruce L Levine, Carl H June, and Michael C. Milone: Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) Blood (ASH Annual Meeting) 130 : #505,2017.

Academic Contact Info

Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-175
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 615-5853
Patient appointments: 800-789-7366 (PENN)